THE NEXT

GENERATION IN
ORTHOBIOLOGICS
 THE ARTHREX DIFFERENCE
Since 1984, Arthrex has been a privately held corporation committed to one thing: providing the finest quality
products and educational services to meet the special needs of surgeons and their patients. Arthrex is dedicated
to creative product development and medical education with an experienced, devoted team of professionals
who are truly committed to continuing this long-term tradition. New product innovation is the heart and soul
of Arthrex and has resulted in the development of more than 1000 products per year for arthroscopic and
minimally invasive orthopedic surgical procedures. Our goal is to make technically demanding surgical
procedures easier, safer and reproducible. Your trust in Arthrex products means you are backed
by a company committed to uncompromising quality and constant product innovation, while
providing you with the most competent technical customer support in the industry.
AUTOLOGOUS BLOOD

TABLE OF CONTENTS
Arthrex ACP® Double-Syringe System 1
Arthrex Angel® cPRP System for PRP Formulations 2
Arthrex Angel® cPRP & Bone Marrow Processing System 3
Bone Marrow Aspiration 4
Viscous Delivery Systems 5
IntraOsseous BioPlasty™ System 6

BONE GRAFTING
ArthroCell™ Cellular Bone Graft 7
AlloSync™ Pure Demineralized Bone Matrix 8
AlloSync™ Demineralized Bone Matrix and BioXpress™ Graft Delivery Device 9
AlloSync™ Demineralized Cancellous Sponges and Cortical Fibers
10
StimuBlast® Demineralized Bone Matrix 11
Revision Bone Dowels 12
Quickset™ Calcium Phosphate Cement 13
Allograft Wedges 14
OSferion – Wedge and Trapezoid 14

CARTILAGE AND MENISCUS

BioCartilage® Extracellular Matrix 15
Cartiform® Viable Osteochondral Allograft

16
Autograft OATS® Set 17
Small Joint OATS® Set 17
OATS® AlloPlug and AlloSync™ Cancellous Plugs 18
Fresh Cartilage 19
Precut Fresh Osteochondral Allograft Cores 19
Allograft OATS® System 20
BioUni® OATS® Instrument Set 21
Talus OATS® Set 22
Meniscus Allografts 22
Meniscal Implantation Techniques 23

SOFT TISSUE
Amnion™ Matrix and Viscous 24
ArthroFLEX® Dermal Allograft 25
Arthrex DX Reinforcement Matrix 26
Tendon Allografts – Construct Grafts 27
Tendon Allografts – Standard Grafts 28

WOUND CARE
JumpStart® Antimicrobial Wound Dressing 29
ProWick® Postoperative Dressing and Cold Therapy System 30

REFERENCES AND ORDERING INFORMATION 31

AUTOLOGOUS BLOOD Arthrex ACP® Double-Syringe System
There has been increased interest in autologous blood products for use in a number of orthopedic therapies.
The main effects of platelet-rich plasma are thought to be caused by growth factors released from the
platelets, which may play a beneficial role within these therapies.

Features and Benefits:

• The Arthrex ACP (Autologous Conditioned Plasma) system allows for rapid and efficient concentration
of platelets and growth factors from autologous blood for use at the treatment site.
• The unique double-syringe design allows for convenient and safe handling, as the whole preparation
process takes place in a closed system.
• The Arthrex ACP system is affordable, easy to use, and has a quick procedure time when compared
to other PRP devices.
• White blood cells, specifically neutrophils, are NOT concentrated within the ACP system. These cells can
cause a detrimental effect on the healing process due to release of degradative proteins and reactive
oxygen species.1,2

ACP/Double Syringe with Cap ABS-10010S

Series I ACP Blood Draw Kit ABS-10011
Series II ACP Blood Draw Kit ABS-10012
Centrifuge 1206-01 Double Syringe
Bucket 1491
Bucket Cap 1492
Counterbalance ABS-10027
Arthrex Biologics Cart ABS-10100

Cap for Double Syringe

Series I ACP Kit

Series II ACP Kit

Arthrex Biologics Cart can be used

for Angel or ACP Centrifuge

The Arthrex ACP double-syringe system is used to facilitate the safe and rapid preparation of autologous platelet-rich-plasma (PRP)
from a small sample of blood at the patient’s point of care. The PRP can be mixed with autograft and allograft bone prior
1 to application to an orthopedic surgical site as deemed necessary by the clinical use requirements.
Arthrex Angel® cPRP System for PRP Formulations

AUTOLOGOUS BLOOD
What sets the Arthrex Angel cPRP System apart from the competition is technology. Using a
proprietary platelet sensor and 1-button automation to prepare customized PRP formulations,
the Angel cPRP System can deliver platelet concentrations up to 18x baseline with adjustable
leukocyte concentrations.

Features and Benefits:

• Proprietary platelet sensor system
• Adjustable platelet concentrations
• Adjustable WBC concentrations
• Flexible processing volume 40 mL-180 mL
• Each processing kit can process 3 cycles
up to 180 mL on the same patient
• Programmable and capable of storing up
to 30 custom processing protocols
• Closed system, delivers PRP, PPP
and RBCs into separate, sterile
compartments

Arthrex Angel System ABS-10060

Arthrex Angel System, Refurbished ABS-10060R
Arthrex Angel Kit ABS-10063
Arthrex Angel PRP Kit ABS-10061T
Arthrex Biologics Cart ABS-10100

2
AUTOLOGOUS BLOOD Arthrex Angel® cPRP & Bone Marrow Processing System
Technology is what sets the Arthrex Angel cPRP System apart from the ®

competition. The Arthrex Angel cPRP & Bone Marrow Processing System uses
proprietary sensor technology and 1-button automation to deliver customized
PRP concentrate from bone marrow aspirate (BMA). The Angel system is the only
device that can provide PRP concentrate from BMA with adjustable cellular levels.
Bone marrow is a rich source of platelets, nucleated cells and progenitor cells.
Arthrex Angel System ABS-10060 Arthrex Angel cPRP &
Arthrex Angel System, Refurbished ABS-10060R Platelet Nucleated Cell Hematopoetic Cell Total Neutrophil
Bone Marrow Concentration (K/mL) Concentration (K/mL) Concentration (K/mL) (x10^6)
Arthrex Angel cPRP & BMA Tray ABS-10062T Processing System
Arthrex Angel cPRP & Powered
BMA 87.7 ± 6.4 24.5 ± 15.6 0.002 ± 0.001 612.1
BMA Kit ABS-10062D
Arrow® OnControl®* System PRP Concentrate
787.0 ± 317.6 240.5 ± 186.6 0.081 ± 0.056 132.9
Sterile Procedure Tray 9403-VC-006 from BMA
Arrow OnControl Power Driver
® ®
Increase Above Baseline ˜9x ˜10x ˜33x 80%
with Cradle 9401
Arthrex Biologics Cart ABS-10100
>80% recovery of the hematopoietic cell lines with an
80% reduction in the undesirable neutrophil cell content.

Arthrex Angel cPRP

& BMA Tray

Arthrex Angel
cPRP & Powered
BMA Kit

Arrow ® OnControl ®
System Sterile
Procedure Tray *

Arthrex Angel cPRP & Bone

Marrow Processing System
Key Features:
• Proprietary platelet sensor system In vitro culture expansion
• Adjustable platelet concentrations of progenitor cells over 96 hours
• Adjustable WBC concentrations
• Programmable – can store up to 30
custom processing protocols
• Flexible processing volume 40 mL-180 mL
• Each processing kit can process three
cycles up to 180 mL, on the same patient
• Closed system, delivers PRP, PPP and
RBCs into separate, sterile compartment

*Arrow and OnControl are registered trademarks of Teleflex, Inc. 48 hrs. 96 hrs.
3
Bone Marrow Aspiration

AUTOLOGOUS BLOOD
Bone marrow-stimulating techniques, like abrasion and microfracturing, have been advocated for over 20
years.3 Bone marrow is a source of stem cells and progenitor cells that differentiate into a variety of tissues
(eg, bone, cartilage, tendon, ligament, fat, muscle, nerve). There has also been discussion that bone marrow
stem cells have a role in the maintenance and repair of several other tissues.4 Because of the plasticity exhibited
by bone marrow, a number of studies have investigated the benefits of bone marrow used:

• Through microfracturing into a collagen matrix for treatment of osteochondral defects4

• With grafts to treat tibial nonunions5,6
• For tendon graft-to-bone interface in rabbit models at early time points7, 8
• For spinal fusion in a rabbit model9
• With growth factors for the treatment of large bony defects in animals10
• With porous ceramic scaffolds implanted in human femoral defects with positive results10

Bone marrow aspirate (BMA) provides a cell suspension that can be readily processed intraoperatively for
immediate implantation. BMA is commonly withdrawn from the iliac crest, but can also be aspirated from
the femur and humerus. BMA can be injected directly to a repair site, localizing a specific volume of BMA
to support and facilitate healing.

Bone Aspiration Kit

The Bone Aspiration Kit is
a convenient, sterile combination
of instruments useful for aspirating
bone marrow arthroscopically.
Bone Aspiration Kit (AR-1101DS) Contents:
1 Bone Marrow Aspiration Needle
1 Syringe, 60 cc
1 Prep Tray

4
AUTOLOGOUS BLOOD Viscous Delivery Systems
Key Features:
• Quick and simple to attach/detach
• Easy to fill – no need to disassemble
• 11:1 ratio allowing homologous mixture of 2 fluids
• Use to provide a low- or high-viscosity fluid Viscous-Gel™ High
Viscosity Ratio Applicator
• Extra long, blunt, fenestrated and beveled delivery needles with 10 cm Mixing Tip
• ACP/PRP can be mixed with allograft or autograft bone prior
to application to an orthopedic surgical site as a spray,
gel or clot

Viscous-Gel Applicator, High Viscosity ABS-10050

Viscous-Spray Applicator, Low Viscosity ABS-10051
Viscous-Spray II Applicator, Low Viscosity ABS-10052
Fenestrated Delivery Needle ABS-20000
Tuohy Delivery Needle ABS-21000
Cannula Bending Tool AR-6650 Viscous-Spray™ Low
Viscosity Ratio Applicator
Micromedics with 3 cm Mixing/Spray Tip
Ratio Applicator Assembly 11:1 Ratio SA-1001
Applicator with Dual Spray Tips 11:1 Ratio SA-1060
16 ga x 10 cm (4 in) SA-3600
20 ga x 5 cm (2 in) SA-3615
20 ga x 10 cm (4 in) SA-3618
20 ga x 18 cm (7 in) SA-3619
20 ga x 26 cm (10.25 in) SA-3620
Dual Cannula Semiflexible Endoscopic,
32 cm SA-3650
Dual Spray Tip SA-3660
Endoscopic Applicator with Mixing Tip, Viscous-Spray II Low
30 cm, 1:1 Ratio SA-3662 Viscosity Ratio Applicator with
Blending Connector with Single Flexible a Clog-resistant Mixing/Spray Tip
Cannula SA-3673
Blending Connector with Single Spray SA-3674
Mixing Applicator Low Viscosity with
Spray Tip SA-3675
Applicator Procedure Kit, 11:1 Ratio SA-4400
Dual Spray Procedure Kit, 11:1 Ratio SA-4460
Gas Assisted Procedure Kit, 11:1 Ratio SA-6111
Applicator Assembly, 3 cc, 1:1 Ratio SA-3303
10 cc Applicator
Assembly, 1:1 Ratio

Fenestrated Delivery
Needle 17-gauge, 14.63 cm
Precontour either delivery from hub, 8 holes along first
needle with the Arthrex 1.27 cm of tip (0.3 mm diameter holes)
Cannula Bending Tool
Gel easily dispersed
from tip

Tuohy Delivery
Needle 17- gauge,
15.07 cm from hub

Adipose Tissue
Harvesting Kit ABS-10055

5
IntraOsseous BioPlasty™ System

AUTOLOGOUS BLOOD
Recent discussions around how to treat symptomatic bone marrow lesions (BMLs) have led to the introduction
of the IntraOsseous BioPlasty (IOBP™) procedure which centers around the ability to treat insufficiency fractures,
persistent bone bruises, BML associated with osteoarthritis and early stages of avascular necrosis. The principles
of the IOBP technique are simple: perform a core decompression then deliver a concentrated dose of PRP
concentrate from BMA using the Arthrex Angel® cPRP & Bone Marrow Processing System. When mixed with
a flowable demineralized bone matrix, such as DBM gel, the biologic material delivered to the bone marrow
lesion contains all of the necessary components to aid bone repair, including an osteoconductive and
osteoinductive scaffold, as well as an osteogenic source of stem cells. Research has shown the positive clinical
outcomes of treating BMLs and persistent bone fracture, or nonunions, with bone marrow concentrate.11 Clinical
outcomes from another study indicate pain and function improves following intraosseous delivery of a biologic
into BMLs associated with osteoarthritis.12 The IntraOsseous BioPlasty procedure is the biologic treatment of
bone marrow lesions with techniques that encourage physiologic bone remodeling and repair.

Arthrex Angel cPRP & BMA Tray ABS-10062T

IOBP Core Decompression
and Delivery Kit, Open Tip ABS-2000-OT

Accessories
Delivery Cannula, 8G x 4.5”, Closed Tip RAN-811-CT
Delivery Cannula, 8G x 6”, Open Tip RAN-815-OT

Note: Demineralized bone matrix gel, provided

separately, may be mixed with the autologous
blood solution.

Concentration of Stem Cells in Clinical Outcomes When

Bone Graft Affect Outcome11 Treating Osteoarthritis12
Baseline
5000 10 Week 24
Success
4000 Failure
8
3000 6

2000 4
1000 2

0 0
Total MSC/cm3 VAS Lequesne Index

6
BONE GRAFTING ArthroCell™ Cellular Bone Graft
Viable Allogenic Cellular Bone Matrix
• Product is moldable and contains donor mesenchymal stem cells,
osteoprogenitor cells and marrow-isolated adult multilineage
inducible (MIAMI) cells supporting osteogenic healing processes
• Includes a proprietary blend of mineralized and demineralized
bone particulate including cortical shavings, crushed cancellous
chips and microparticulate bone

Key Features:
• A safe/nonimmunogenic cellular bone matrix intended for use
as a bone void filler for bone defects, fusions and nonunion
orthopedic applications
• Osteogenic, osteoconductive and osteoinductive potential
• Final product is moldable for ease of use and optimal handling
• Novel cryoprotectant (DMSO-Free) and noncytotoxic
• Convenient: stored in a cryogenic freezer (-65˚C) up to 2 years

ArthroCell Cellular Bone Graft, 2.5 cc ABS-2009-02

ArthroCell Cellular Bone Graft, 5.0 cc ABS-2009-05
Mixing Delivery Syringe, 14 cc ABS-2000

Gel Microparticulate Bone Cell Vial

7
 PURE
AlloSync™ Pure Demineralized

BONE GRAFTING
Bone Matrix
AlloSync Pure dehydrated osteoinductive demineralized bone matrix is derived from 100% human allograft
bone with no extrinsic carriers. AlloSync Pure bone matrix resists irrigation and can be used in a fluid environment
(Figure 2). The clinician can control the handling properties of AlloSync Pure bone matrix, which includes
decreasing the viscosity for injectable applications or increasing the viscosity to add autograft and/or allograft.
The proprietary rice-shape fiber technology used to process AlloSync Pure bone matrix increases the
osteoinduction and osteoconductive surface area to accelerate cellular ingrowth.

Features and Benefits:

• Derived from 100% human allograft bone without any extrinsic carriers
• Every lot poststerilization is tested in vivo to ensure osteoinductivity
• Demineralization process preserves native bone morphogenetic proteins (BMPs) and growth factors
• Resists irrigation
• Histologically proven to contain all 5 elements of bone formation including new bone, bone marrow,
osteocytes, chondrocytes and cartilage postimplantation at 28 days13 (Figure 1)
• May be hydrated with bone marrow concentrate (BMC), platelet-rich plasma (PRP), blood, saline
or other cellular components
• Sterile to device grade standards (10-6) and stored at ambient temperature
• Provided in a ready-to-use mixing jar
• 4 sizes available
• 5-year shelf life

Figure 1: AlloSync Pure demineralized bone matrix histology

Figure 2: AlloSync Pure demineralized bone matrix

can be used in an arthroscopic environment. 8
BONE GRAFTING AlloSync™ Demineralized Bone Matrix
AlloSync Bone Products May Provide Osteoinductive
and Osteoconductive Properties: Comparison of Two DBMs
• Osteoinduction – signaling molecules such as bone
morphogenetic proteins (BMPs) that aid in cell
differentiation down osteoblastic pathways
• Every lot of demineralized bone matrix (DBM) is tested
for osteoinductive potential, using either an in vitro assay
or in vivo model
• Osteoconduction – scaffolding from DBM particles
for osteoblasts to form new bone
RPM Carrier Glycerol Carrier
• Additional scaffolding properties are provided in
AlloSync cancellous bone (CB) with the addition of
cancellous bone chips

Superior Handling Characteristics via the Reverse

Phase Medium (RPM) Carrier:
• RPM is an inert, biocompatible co-polymer consisting
5 Minutes Immersion Time
of polypropylene oxide and polyethylene oxide
• Material is flowable at room temperature and thickens
to become more viscous at body temperature
• RPM allows the DBM graft to be moldable and packed AlloSync Gel
into any defect size or shape
• AlloSync bone products will resist irrigation and can AlloSync
be used in a fluid environment without the fear Putty
of graft migration, unlike some other DBMs

AlloSync Bone Products Offer Ease of Use

and Terminal Sterility:
• Provided as a ready-to-use, off-the-shelf product
that requires no thawing or premixing preparation
• Terminal sterilization using electron beam results in
a Sterility Assurance Level (SAL) of 10-6 – process
BioXpress Graft
is not harmful to the DBM or its bioactivity Delivery Device
– Some competitive DBM products are only offered
as aseptically processed products – SAL of 10-3
• Room temperature storage
TM

AlloSync DBM Putty

Putty, 1 cc ABS-2012-01
Putty, 2.55 cc
Putty, 5 cc
ABS-2012-02
ABS-2012-05
BioXpress™ Graft Delivery Device
Putty, 10 cc ABS-2012-10 The BioXpress graft delivery device is
AlloSync DBM Gel
designed for targeted delivery of hydrated

Gel, 1 cc ABS-2013-01 allograft, autograft, or synthetic bone graft
Gel, 5 cc ABS-2013-05 materials to an orthopedic surgical site, Blunt
Gel, 10 cc ABS-2013-10 while maximizing material utilization. Tip
AlloSync CB DBM Putty
BioXpress Graft Delivery Device, Vented
Putty, 5 cc ABS-2014-05
Blunt Tip Cannula, 10 cm ABS-10053-10
Putty, 10 cc ABS-2014-10
Angled Tip Cannula, 10 cm ABS-10053-10-45 Angled
AlloSync CB DBM Paste Blunt Tip Cannula, 15 cm
ABS-10053-15 Tip
Paste, 1 cc ABS-2015-01 Angled Tip Cannula, 15 cm ABS-10053-15-45
Paste, 3 cc ABS-2015-03
Paste, 8 cc ABS-2015-08
Cancellous Crushed, 5 cc 27715005

AlloSync bone products are indicated for orthopedic applications as filler for gaps or
voids that are not intrinsic to the stability of the bony structure. AlloSync bone products
are indicated to be packed gently into bony gaps in the skeletal system as a bone graft
extender (extremities, spine and pelvis) and as bony void filler of the extremities and pelvis.
9 These defects may be surgically created or from the result of traumatic injury to the bone.
AlloSync™ Demineralized Cancellous

BONE GRAFTING
Sponges and Cortical Fibers
Cancellous Sponges Features and Benefits:
Demineralized
• Every lot poststerilization is tested in vivo to ensure osteoinductivity Cancellous Sponges
• Demineralized cancellous matrix comprised of 100% cancellous bone and Cortical Fibers
• Maintains natural bone architecture with interconnected porosity
• Provides optimal scaffold for cellular attachment and proliferation
• Contains exposed natural growth factors with verified osteoinductivity
• Naturally absorbs and retains bioactive fluids like platelet-rich plasma (PRP)
and bone marrow aspirate (BMA)
– After rehydration, the product is compressible like a sponge, allowing
for flexibility to fit in and around different types of bone defects
• Sterile to device grade standards (10-6) and stored at ambient temperature Cubes

Demineralized Cortical Fibers Features and Benefits:

• New form of 100% DBM offering excellent handling characteristics
without the need for an additional carrier
• Osteoconductive and verified osteoinductive properties
– The cortical fibers are demineralized using CellRight Technologies’
proprietary process, optimizing the residual calcium level and
osteoinductivity
Strips
– Demineralized cortical fibers provide an optimal scaffold for cellular
attachment and proliferation
• Customizable hydration: naturally wicks up bioactive fluids such as
PRP and BMA
• Sterile to device grade standards (10-6) and stored at ambient temperature

Cancellous Sponges
Cube, 8 mm x 8 mm x 8 mm ABS-2005-01
Cube, 10 mm x 10 mm x 10 mm ABS-2005-02
Cube, 12 mm x 12 mm x 12 mm ABS-2005-03 Chips

Strip, 10 mm x 10 mm x 3 mm ABS-2006-01
Strip, 15 mm x 40 mm x 3 mm ABS-2006-02
Strip, 26 mm x 19 mm x 3 mm ABS-2006-03
Strip, 10 mm x 20 mm x 7 mm ABS-2006-04

Chips (1 mm - 4 mm), 1.0 cc ABS-2007-01

Chips (1 mm - 4 mm), 2.5 cc ABS-2007-02
Chips (1 mm - 4 mm), 5 cc ABS-2007-03

Cortical Fibers Fibers
Fibers, 1.0 cc ABS-2008-01
Fibers, 2.5 cc ABS-2008-02
Fibers, 5 cc ABS-2008-03
Fibers, 10 cc ABS-2008-04

AlloSync Pure Demineralized Bone Matrix

1.0 cc ABS-2010-01
2.5 cc ABS-2010-02
5.0 cc ABS-2010-05
10 cc ABS-2010-10

AlloSync demineralized strip used to

augment an ankle arthrodesis procedure
10
BONE GRAFTING StimuBlast® Demineralized Bone Matrix
StimuBlast Bone Products May Provide Osteoinductive
and Osteoconductive Properties:
• Osteoinduction – signaling molecules such as bone morphogenetic proteins
(BMPs) that aid in cell differentiation down osteoblastic pathways
• Every lot of demineralized bone matrix (DBM) is tested for osteoinductive potential,
using either an in vitro assay or in vivo model
• Osteoconduction – scaffolding from DBM particles for osteoblasts to form new bone
• Additional scaffolding properties are provided in StimuBlast cancellous bone (CB)
with the addition of cancellous bone chips

Superior Handling Characteristics via the Reverse

Phase Medium (RPM) Carrier:
• RPM is an inert, biocompatible co-polymer consisting of polypropylene oxide
and polyethylene oxide
• Material is flowable at room temperature and thickens to become more viscous
at body temperature
• RPM allows the DBM graft to be moldable and packed into any defect size or shape
• StimuBlast bone products will resist irrigation and can be used in a fluid environment
without the fear of graft migration, unlike some other DBMs

StimuBlast Bone Products Offer Ease of Use and Terminal Sterility:

• Provided as a ready-to-use, off-the-shelf product that requires no thawing
or premixing preparation
• Terminal sterilization using electron beam results in a Sterility Assurance
Level (SAL) of 10-6 – process is not harmful to the DBM or its bioactivity
– Some competitive DBM products are only offered
as aseptically processed products – SAL of 10-3
• Room temperature storage

StimuBlast DBM Putty

Putty, 1 cc ABS-2012-01
Putty, 2.55 cc ABS-2012-02
Putty, 5 cc ABS-2012-05
Putty, 10 cc ABS-2012-10
StimuBlast DBM Gel
Gel, 1 cc ABS-2013-01
Gel, 5 cc ABS-2013-05
Gel, 10 cc ABS-2013-10
StimuBlast CB DBM Putty
Putty, 5 cc ABS-2014-05
Putty, 10 cc ABS-2014-10
StimuBlast CB DBM Paste
Paste, 1 cc ABS-2015-01
Paste, 3 cc ABS-2015-03
Paste, 8 cc ABS-2015-08
Cancellous Crushed, 5 cc 27715005
OsteoPrecision Graft Delivery Device - Vented
Cannula, 10 cm GD-1115-100
Cannula, 15 cm GD-1115-150

StimuBlast bone products are indicated for orthopedic applications as filler for gaps or voids that are not intrinsic to the stability of the bony structure.
StimuBlast bone products are indicated to be packed gently into bony gaps in the skeletal system as a bone graft extender (extremities, spine and
11 pelvis) and as bony void filler of the extremities and pelvis. These defects may be surgically created or from the result of traumatic injury to the bone.
Revision Bone Dowels

BONE GRAFTING
Revision Bone Dowels offer surgeons a quick and effective solution for filling bone tunnels during staged
ACL/PCL revision cases. The use of bone dowels provides an immediate structural and biologic architecture
for stability and incorporation. Soaking the dowels in PRP or bone marrow concentrate provide an infusion
of growth factors and cells to assist with the incorporation of the scaffold.

The Revision Bone Dowels were treated with the Allowash XG®* process to clean the scaffold and then
preshaped with a tapered tip and cannulated for easier implantation. Treatment with the Preservon®*
technology allows for the Revision Bone Dowels to be stored in a prehydrated state for up to five years.

Features and Benefits:

• Ready to use
• Prehydrated with Preservon® technology
• 5-year shelf life
• 10-6 Sterility Assurance Level
• Cannulated
• Bullet design

D
L

Length (L) 25 mm-29 mm Length (L) 30 mm-35 mm

LifeNet Health
Diameter (D) Part Number
9 mm PCD9
10 mm PCD10
11 mm PCD11
12 mm PCD12
13 mm PCD13
14 mm PCD14
16 mm PCD16
18 mm PCD18
LifeNet Health
Diameter Part Number
9 mm PCDXL9
10 mm PCDXL10
11 mm PCDXL11
12 mm PCDXL12
13 mm PCDXL13
14 mm PCDXL14
16 mm PCDXL16
18 mm PCDXL18

*Allowash XG and Preservon are registered trademarks of LifeNet Health. 12

BONE GRAFTING Quickset™ Calcium Phosphate Cement
Features and Benefits:
Quickset cement is a macroporous, injectable, hardening, resorbable
bone cement provided in an easy-to-use, closed mixing system.

Composition:
• The mixing system is a dual-chambered syringe containing
a powder and mixing liquid
• The powder chamber contains a mixture of calcium phosphates
and an organic polysaccharide polymer – the polysaccharide
is a highly biocompatible polymer that optimizes the viscosity,
cohesiveness, and macroporosity
iBalance® HTO
• The mixing liquid consists of a sodium phosphate solution which
facilitates the setting time (crystallization) of the cement
• The end product is a calcium-deficient apatite very similar
to the mineral phase of bone

Physical and Chemical Properties:

• Global porosity of 70%
– Microporosity (<10 µm): 88%
– Mesoporosity (10 -100 µm): 2%
– Macroporosity (>100 µm): 10%
• Porosity is present by the time it reaches complete hardening Pilon Fracture
(24 hours after implantation)
• Mechanical compressive strength of 24 MPa
(24 hours after implantation)
• Excellent cohesiveness, which prevents “wash-out“ by biological fluids
• No shrinkage during crystallization
• Nonexothermic reaction
• Radiopaque

Preparation:
• Mixing time (room temperature): 2 minutes
Calcaneus Fracture
• Injection time (room temperature): 2 minutes
• Initial setting time (body temperature): 8 minutes
– Time it takes for the product to no longer be flowable. Manipulation
during this time period is not recommended, as it will affect the
crystallization process and final strength characteristics.
• Complete hardening (body temperature): 24 hours

Arthrex Quickset Cement, 5 cc ABS-3005

Arthrex Quickset Cement, 8 cc ABS-3008
Arthrex Quickset Cement, 16 cc ABS-3016

Quickset cement is intended for bony voids or defects that are not intrinsic to the stability of the bony structure. Quickset cement is intended to be placed or
injected into bony voids or gaps of the skeletal system (ie, the extremities and pelvis). These defects may be surgically created osseous defects or osseous
defects created from traumatic injury to the bone. The product provides bone void filler that resorbs and is replaced with bone during the healing process.
13 Arthrex Quickset cement is available in the US as a convenience kit containing Arthrex Quickset cement, a cannula and a delivering gun.
Allograft Wedges

BONE GRAFTING
Allograft bone wedges with cortical/cancellous bone provide the surgeon with a number of options.
The high quality bone allografts provide many benefits when compared to autograft iliac crest wedges:
no donor site morbidity, no secondary incision site to recover the autograft which reduces the opportunity
for an infection, hematoma, or pain at that site and reduced operative time.

Allograft Wedges JRF Ortho Part Number Two freeze-dried wedges with the following
Osteotomy Wedge Set for HTO 41915001 dimensions are provided in the set:
Width = 20 mm
High Tibial
Osteotomy
Length = 50 mm
Wedge Height = 17.5 mm
OSferion
OSferion is an osteoconductive bone graft substitute and bone void filler consisting of 100% high-purity
beta-tricalcium phosphate (ß-TCP). OSferion’s micro- and macroporous structure allows it to be resorbed
and replaced by bone during the healing process when used in conjunction with rigid fixation devices.

OSferion wedges are intended to be used in conjunction with the distal femoral and high tibial opening
wedge osteotomy plates and screws to promote healing and provide added rigidity to the repair.

Features and Benefits:

• Allows for simultaneous controlled absorption and promotion of osteogenesis
• Micro- and macroporous structure promotes vascularization14 and the entry of
proteins into cells for bone formation15
• Optimum pore diameter facilitates maximum cell infiltration
• The material has a compressive force of up to 20 MPa (2900 pounds/inch2)

OSferion Trapezoids:
• Intended to be used as a bone-patellar tendon-bone (BTB) graft harvest site bone void filler in the patella and tibia
• OSferion naturally wicks up autologous blood and/or bone marrow
• Can easily be customized using a rongeur or oscillating saw
• Clinical studies have shown that the BTB graft harvest site bone void filling reduces
the incidence of patella fracture, anterior knee pain, and postoperative kneeling pain

OSferion Osteotomy Wedge

OSferion Osteotomy Wedge, 7 mm x 30 mm AR-13370-1
OSferion Osteotomy Wedge, 10 mm x 30 mm AR-13370-2
OSferion Osteotomy Wedge, 12 mm x 35 mm AR-13370-3 Arthrex Quickset™ calcium phosphate
OSferion Osteotomy Wedge, 15 mm x 35 mm AR-13370-4 cement and OSferion wedge used to
fill the bony void created during an
OSferion Trapezoid iBalance® HTO procedure.
OSferion Trapezoid, 8 x 25 x 7 mm x 75° AR-13372-1
OSferion Trapezoid, 9 x 25 x 7 mm x 75° AR-13372-2
OSferion Trapezoid, 10 x 25 x 7 mm x 75° AR-13372-3

Serial Postoperative X-rays

1 week 3 months 6 months

OSferion trapezoid used to fill the bony void that remains after harvesting a BTB graft.
14
CARTILAGE AND MENISCUS BioCartilage® Extracellular Matrix
BioCartilage extracellular matrix was designed to provide a reproducible, simple and inexpensive method to
augment traditional marrow stimulation procedures. Scientific evidence exists supporting the premise that a
dehydrated, allograft-cartilage scaffold used as an adjunct to marrow stimulation should improve the degree
and quality of tissue healing within a properly prepared articular cartilage defect.16,17 Primate study indicates
repopulation of the defect with hyaline-like cartilage at 12 weeks.18

BioCartilage extracellular matrix is an injectable cartilage-scaffold paste that can fill a cartilage defect subsequent
to marrow stimulation. Difficult-to-reach focal defects can be treated open or arthroscopically with a unique
delivery system.

Features and Benefits

Figure 1. Immunohistochemistry
staining for type II collagen*
Composition: Cartilage Extracellular Matrix
• BioCartilage allograft contains the extracellular matrix that is native to
articular cartilage including key components such as type II collagen
(Figure 1), proteoglycans (Figure 2), and additional cartilaginous growth factors
• After processing, the dehydrated allograft cartilage has a particle size
of 100 μm-300 μm:
– The small particle size improves its injectable nature after it is mixed with
an autologous blood solution allowing easier delivery to the defect site
– The small particle size also increases the surface area, providing
attachment sites for the patient’s bone marrow cells
• The principle of BioCartilage extracellular matrix is to serve as a scaffold
over an articular cartilage defect providing a tissue network that can
potentially signal autologous cellular interactions
• Marrow elements will fill the cartilage lesion and interact with the scaffold
created by BioCartilage extracellular matrix instead of being expected to
create its own fibrin scaffold, as typically anticipated from a marrow
stimulation procedure

Processing:
• BioCartilage extracellular matrix goes through a specialized, gentle
dehydration process that allows the water content to be removed
• After dehydration, the cartilage advances through a number of proprietary
processing steps resulting in a very consistent particle size range
Figure 2. Toluidine blue stain
• BioCartilage extracellular matrix is a cartilage scaffold that is aseptically
highlighting proteoglycan content*
processed and packaged to allow for ambient temperature storage with
a shelf life of 5 years

BioCartilage Extracellular Matrix, 0.75 cc ABS-1007-BC Recommended Accessories

BioCartilage Extracellular Matrix, 1 cc ABS-1010-BC
Mixing and Delivery Kit, Large Joint ABS-1000-L
(Includes Mixing Syringe and Cap,
Arthroscopic Delivery Needle,
Obturator, Funnel, Fat Pad Retractor,
and Cannulated Swabs)
Mixing and Delivery Kit, Small Joint ABS-1000-S
(Includes Mixing Syringe and Cap,
Arthroscopic Delivery Needle,
Obturator, Funnel, Fat Pad Retractor,
and Cannulated Swabs)
Long Tuohy Delivery Needle
and Obturator ABS-1001-L
PowerPick™ XL Microfracture
Instrument, 45°, 6 mm depth AR-8150PX-45
Gemini SR8 Cannula AR-6572
Switching Stick, 2.6 mm x 305 mm AR-6572S
Chondral Pick, straight 30° tip AR-8655-05
Ring Curette, reverse angle AR-8655-04
Noninvasive Ankle Distractor Set AR-1713S
Ankle Arthroscopy Distractor Strap AR-1712
Ankle Arthroscopy Set AR-8655S

15 *The tissue was stained after the dehydration step 15

Cartiform®* Viable Osteochondral Allograft

CARTILAGE AND MENISCUS

Cartiform allograft is a cryopreserved osteochondral allograft composed
of viable chondrocytes, chondrogenic growth factors and extracellular matrix
proteins. While maintaining an intact cartilage structure (Figure 1), the bony
portion of the osteochondral allograft is minimal and the graft is porated
to offer unique handling characteristics and simple fixation techniques.

Cartiform viable osteochondral allograft is recovered with minimal bone

and porated for a variety of reasons:
• The minimal bone and pores impart flexibility to the allograft,
thereby improving handling characteristics for implantation
and fixation (Figure 2)
• The pores increase the surface area and allow for the
proprietary cryopreservative solution to penetrate the tissue
Superficial
and preserve chondrocyte viability throughout the allograft
• The pores facilitate enhanced growth factor release from
Cartiform viable osteochondral allograft and allow for progenitor
cell migration into the graft following implantation in the
osteochondral lesion Transitional

Cartiform viable osteochondral allograft combines the safety and

success of traditional fresh stored osteochondral allografts with
ease of use as the graft is trimmable and flexible to match any
lesion size and contour. Radial

Stored in a proprietary cryopreservative solution, Cartiform viable

osteochondral allograft is readily available with a 2-year shelf life
when stored at -80° C. Experimental testing of Cartiform viable
osteochondral allograft indicates that >72% cell viability, post-thaw, Osseous
is maintained beyond 2 years (Figure 3).19
Figure 1. Structural organization
Cartiform Viable Osteochondral Allograft, 10 mm Disc ABS-1101-10 of Cartiform allograft. Cartiform
Cartiform Viable Osteochondral Allograft, 12 mm x 19 mm ABS-1102-19 viable osteochondral allograft
Cartiform Viable Osteochondral Allograft, 20 mm Disc ABS-1101-20 preserves the microstructure of
Cartiform Viable Osteochondral Allograft, 20 mm x 25 mm ABS-1102-25 3 distinct cartilage zones (super-
ficial, transitional or radial) and
an osseous layer as evident on
histological staining (H&E).

Figure 3. Live (green) and dead

(red) cell-staining of Cartiform unit
post-thaw after 2.7 years storage
at -80° C, 70% cell viability.

Fixation of Cartiform viable osteochondral allograft in
the trochlea is achieved with the Knotless SutureTak®
percutaneous insertion kits.
B C
Figure 2. Appearance of Cartiform viable
osteochondral allograft (20 mm diameter
size): top (A), bottom (B), and side (C) views.
Note the score mark distinguishing the
bottom (bone) side (outlined with black
box in B and the flexibility that enables
folding in C).
16
CARTILAGE AND MENISCUS Autograft OATS® Set
The Autograft OATS (Osteochondral Autograft Transfer System) technique is an excellent procedure for the
repair of small osteochondral defects of the knee. Surgeons may use single-use OATS instrumentation to
facilitate the harvest of osteochondral/hyaline cartilage cores from a donor site superior and
lateral to the notch or above the sulcus terminalis.

Single-Use OATS Set, 4.75 mm AR-1981-04S

Single-Use OATS Set, 6 mm AR-1981-06S
Single-Use OATS Set, 8 mm AR-1981-08S
Single-Use OATS Set, 10 mm AR-1981-10S
OATS Sizer/Tamps Instrumentation Set AR-1985S
Set includes a size-specific sizer/tamp within each package

Single-Use OATS Set

Small Joint OATS® Sets

The Small Joint Osteochondral Autograft Transfer System (OATS) kit is a sterile, single-use set for
the removal of osteochondral defects and transfer of autograft plugs to replace the defect. The
set includes everything needed to perform this procedure on either the talus or the metatarsals.

The defect at the recipient site is drilled out using

the guide pin and cannulated drill. The graft plug is
harvested from a donor site to a controlled depth
just longer than the depth of the drill hole at the
recipient site. The graft plug is trimmed to length
and press-fit into the recipient site with an
extruder and/or tamp.

Cartilage Replaces Cartilage – Whether

harvesting from the patient or an allograft,
Small Joint OATS Set
the patient will have a natural bearing surface
Straightforward Reliable Technique – The well-
documented success of the OATS procedure is,
in large part, due to the ease of use of this set
Sterile, Single-Use Set – Ensures that all the
necessary instruments are present and ready

Small Joint OATS Set, 6 mm AR-8981-06S

Small Joint OATS Set, 8 mm AR-8981-08S
Small Joint OATS Set, 10 mm AR-8981-10S
Metatarsal and Talar
OATS Technique

17
 CARTILAGE AND MENISCUS
OATS® AlloPlug and AlloSync™ Cancellous Plugs
Surgeons concerned about possible donor site morbidity, caused by leaving the donor site sockets open,
may now use these specially designed OATS AlloPlug backfill plugs to fill the donor site and promote
natural bone healing for a complete biologic repair.

AlloPlugs are processed from the articular surface, resulting in a multiphasic plug composed of a dense
cancellous layer, a cortical layer, and a cartilage layer. These plugs come in a range of sizes from 7 mm-11 mm
in diameter and 16 mm in length.

AlloSync cancellous plugs are comprised of 100% human cancellous bone for use in backfill and bone void
procedures. These plugs are provided sterile via the Allowash XG®* process and stored in Preservon®*,
a proprietary glycerol-based preservation technology that allows allografts to be stored in a fully hydrated
state at ambient temperature. Preservon preservation technology eliminates the lengthy thawing and
rehydrating times and does not require freezer storage. These plugs are available in sizes from
6 mm-11 mm in diameter and 16 mm in length.

When selecting a graft for backfill applications, the implant should be sized 1 mm larger than the OATS core
harvested. For example, in a case where an 8 mm OATS Harvester is used, a 9 mm Allograft Plug is used to
provide a line-to-line fit in the donor site.

An additional Allograft Plug Delivery Sleeve may be ordered to facilitate implantation of the plug.
Arthrex LifeNet Health
Part
Number Part Number
AlloPlug Frozen Backfill Plug w/Cartilage, 7 mm FCPD7
AlloPlug Frozen Backfill Plug w/Cartilage, 8 mm FCPD8
AlloPlug Frozen Backfill Plug w/Cartilage, 9 mm FCPD9
AlloPlug Frozen Backfill Plug w/Cartilage, 10 mm FCPD10
AlloPlug Frozen Backfill Plug w/Cartilage, 11 mm FCPD11
AlloSync Cancellous Plug, 6 mm PCPD6
AlloSync Cancellous Plug, 7 mm PCPD7
AlloSync Cancellous Plug, 8 mm PCPD8
AlloSync Cancellous Plug, 9 mm PCPD9
AlloSync Cancellous Plug, 10 mm PCPD10
AlloSync Cancellous Plug, 11 mm PCPD11
Allograft Plug Delivery Sleeve, 7 mm AR-1981BI-07
Allograft Plug Delivery Sleeve, 9 mm AR-1981BI-09
Allograft Plug Delivery Sleeve, 11 mm AR-1981BI-11

Allograft Plug Delivery Sleeve

• Cartilage
• Cortical Bone
• Cancellous Bone

*Allowash XG and Preservon are registered trademarks of LifeNet Health. 18

CARTILAGE AND MENISCUS Fresh Cartilage
Arthrex has a long-standing partnership with leading tissue banks to provide fresh osteochondral
allografts (OCA) for use in joint restoration procedures. Fresh OCAs allow the surgeon to transplant
mature, hyaline cartilage with viable chondrocytes and subchondral bone in a single procedure.
JRF Ortho LifeNet Health
Upper Extremity/Shoulder Part Number Part Number
Humeral Head, Right 41247001 HHR80
Humeral Head, Left 41247002 HHL80
Elbow
Distal Humerus, Right 44647001
Distal Humerus, Left 44647002
Proximal Ulna, Right 45847001 Lateral Partial
Lateral Femoral
Proximal Ulna, Left 45847002 Hemi-Condyle
Hemi-Condyle
Lower Extremity/Hip
Femoral Head, Right 41847001 FHR80
Femoral Head, Left 41847002 FHL80
Knee
Medial Partial Hemi-Condyle, Right 43647001 PCC80
Medial Partial Hemi-Condyle, Left 43647002 PCB80
Lateral Partial Hemi-Condyle, Right 43747001 PCD80
Lateral Partial Hemi-Condyle, Left 43747002 PCA80
Medial Femoral Hemi-Condyle, Right 32247001 FCC80 Medial Hemi-Tibial
Medial Femoral Hemi-Condyle, Left 32247002 FCB80 Plateau w/Meniscus
Lateral Femoral Hemi-Condyle, Right 32147001 FCD80
Lateral Femoral Hemi-Condyle, Left 32147002 FCA80 Patella Bone
Whole Femoral Condyle, Right 33547001 FCR80 w/Attachment
Whole Femoral Condyle, Left 33547002 FCL80
Femoral Trochlea, Right 43547001 FTR80
Femoral Trochlea, Left 43547002 FTL80
BiCompartment, Right Lateral
and Trochlea 43747003 FTD80
BiCompartment, Left Lateral
and Trochlea 43747004 FTA80 Distal Tibia
BiCompartment, Right Medial
and Trochlea 43647003 FTC80
BiCompartment, Left Medial Humeral Head
and Trochlea 43647004 FTB80
Medial Hemi-Tibial Plateau
w/Meniscus, Right 44947001
Medial Hemi-Tibial Plateau
w/Meniscus, Left 44947002
Lateral Hemi-Tibial Plateau
Femoral Trochlea Talus
w/Meniscus, Right 45047001
Lateral Hemi-Tibial Plateau
w/Meniscus, Left 45047002
Whole Tibial Plateau w/Meniscus, Right 32447001 TFR80 Precut, fresh OCA Core
Whole Tibial Plateau w/Meniscus, Left 32447002 TFL80
Patella Bone w/Attachment, Right 33647001 PAR80
Patella Bone w/Attachment, Left 33647002 PAL80
Foot and Ankle
Distal Tibia, Right 32747001 TDR80
Distal Tibia, Left 32747002 TDL80
Talus, Right 32647001 ATR80
Talus, Left 32647002 ATL80
Proximal Metatarsal Bone, Right 44747001
Proximal Metatarsal Bone, Left 44747002
Distal Metatarsal Bone, Right 44847001
Distal Metatarsal Bone, Left 44847002

JRF Ortho Ordering Information

Precut Osteochondral Core, Fresh, 10 mm 45647010
Precut Fresh Osteochondral Precut Osteochondral Core, Fresh, 15 mm 45647015
Allograft Cores
Precut osteochondral allograft (OCA) cores provide a biologic and structural repair for full
thickness osteochondral lesions. The OCA cores provide the optimal architecture, biomechanical
support, and viable hyaline cartilage to support the repair during healing. The availability of fresh
OCA cores now provides surgeons with a convenient and new tool in their cartilage treatment
regimen without the challenge of harvesting sufficient and suitable autologous donor cartilage.
19
Allograft OATS® System

CARTILAGE AND MENISCUS

The Allograft OATS system can be used for intraoperative harvesting of 15 mm–35 mm-diameter cores
from fresh allografts.

There are few treatment options for patients with large symptomatic lesions of osteoarticular surfaces.
Using allografts for osteoarticular resurfacing gives surgeons the ability to match the contour and cartilage
morphology of the recipient site, while avoiding multiple surgical sites and the possible donor site morbidity
associated with recovering an autograft from the knee. Fresh grafts are stored in a proprietary storage
media and maintained at 4º C. These grafts should be implanted as soon as possible to have the highest
levels of viable chondrocytes.

The Allograft OATS Instrumentation Set

is provided at no charge when working
with your Arthrex Technology Consultant
to secure a fresh talus through an Arthrex
tissue partner.

Allograft OATS Instrument Set

AR-4075S

20
CARTILAGE AND MENISCUS BioUni™ OATS® Instrument Set
The BioUni OATS Instrument Set is the new standard for restoration of the articular surface when presented
with elongated cartilage defects in the medial femoral condyle. Through a series of precisely designed cutting
instruments, surgeons can replace damaged cartilage with a single, elliptical piece of viable, hyaline cartilage.

The BioUni instruments address many of the challenges and risks associated with the recovery and implantation
of multiple small and large cartilage cores. Overlapping multiple cores adds complexity of curve matching,
fit and surgical time for each procedure. The BioUni instruments were designed to match the natural curvature
of the femoral condyle to remove those complexities. Multiple sizes allow flexibility for the surgeon to adjust
the width and length of the cartilage defect and to ensure proper restoration of the articular surface with a
single cartilage piece.

BioUni OATS Instrument Set AR-4080S

Accessories
PowerPick™ Microfracture Instrument, 45’ 6 mm Depth AR-8150PX-45
PowerPick Microfracture Instrument, 30’ 4 mm Depth AR-8150PP-30
PowerPick Microfracture Instrument, 45’, 6 mm Depth (5 pack) AR-8150PP-45
Autologous Conditioned Plasma (ACP) ABS-10010S
AlloSync™ Gel, 1 cc ABS-2002-01
AlloSync Gel, 5 cc ABS-2002-05

Final look at the BioUni cartilage

21
Talus OATS® Instrumentation Set

CARTILAGE AND MENISCUS

The Talus OATS Instrumentation Set facilitates harvesting of small diameter (6 mm-12 mm) osteochondral/
hyaline cartilage cylinders from an allograft bone. The core is made by placing the fresh talus into the
workstation and harvesting it with the donor harvester. A recipient socket is created 0.5 mm undersized
with the appropriately sized recipient harvester. The exact depth of the allograft, to match the socket,
is obtained with the Depth Measurement Guide and the allograft is trimmed to the same depth and
obliquity. Dilation of the socket results in a line-to-line fit once the donor allograft is inserted into the
recipient socket. Final seating of the allograft is achieved with an oversized tamp, resulting in a
perfectly flush, press-fit graft that does not require fixation implants.

The Talus OATS Instrumentation Set is provided

at no charge when working with your Arthrex
Technology Consultant to secure a fresh talus
through an Arthrex tissue partner.

Talus OATS Instrument Set

AR-8900S

Meniscus Allografts
Better understanding of the biomechanical consequences of total and partial meniscectomy has led surgeons
to explore methods of meniscus preservation. However, in many cases, the damage is far too extensive to
preserve the meniscus and few options exist for these patients.

Meniscal allografts have proven to be effective in improving function and reducing pain for selected patients
with a meniscus-deficient knee. Arthrex can provide medial and lateral meniscal allografts that come with
sufficient bone block to perform various anchorage procedures including double-bone plug, keyhole and
dovetail technique.

Meniscal allografts are most commonly used in symptomatic patients with prior meniscectomy and persistent
pain. Patients should have normal alignment and should not have articular damage greater than grade III.
Serious articular disease, osteophyte formation or flattening of the femoral condyle are common
contraindications for meniscal transplant.

JRF Ortho Part Number LifeNet Health Part Number

Lateral Meniscus, Right 28325001 FMN RL
Lateral Meniscus, Left 28325002 FMN LL
Medial Meniscus, Right 28225001 FMN RM
Medial Meniscus, Left 28225002 FMN LM

Meniscal allograft tissue is also available upon request

for nonknee transplantation such as carpometacarpal
or metatarsophalangeal joint procedures. 22
CARTILAGE AND MENISCUS Meniscal Implantation Techniques
Meniscal allografts have been found to be a feasible alternative in the effort to limit sequelae of arthritis
that can occur with meniscal excision. The surgical technique for meniscal allograft transplantation of the
knee continues to evolve.

Simplified graft preparation and recipient tibia preparation – to allow for the transplant to be positioned
anatomically and anchored with reliable fixation – is the ultimate goal of the procedure.

Double-Bone Plug Meniscal Reconstruction

The double-bone plug technique for meniscal
allograft reconstruction provides a method for
implanting the meniscal allograft with rigid fixation
at the horn attachments. It has been demonstrated
that bony fixation at the attachment site allows for
the maintenance of functional hoop stress by the
meniscal allograft.20

RetroConstruction Drill
Guide Set AR-1510S

Dovetail Meniscal Reconstruction

The dovetail technique simplifies graft preparation
with a time-saving series of cuts preparing the bone
component of the graft to sit securely in the recipient
semitrapezoidal slot created in the tibia. A matching
semitrapezoidal-shaped recipient slot created in the
tibia with a series of step drills, rasps and dilators
matches the bone block preparation.
A “box” technique that requires an interference
screw fixation is also available

The Dovetail Meniscal Allograft Instrumentation

Set is provided at no charge when working
with your Arthrex Technology Consultant
to secure a meniscus allograft.

23 For more information about these meniscal implantation techniques, please access www.Arthrex.com.
Arthrex Amnion™ Matrix and Viscous

SOFT TISSUE
Amniotic-derived tissues contain regenerative qualities and
growth factors that maintain the natural healing properties
of Amnion. Arthrex Amnion Matrix is an anatomical barrier
that helps provide mechanical protection to prevent adhesion
and scar formation while supporting healing with nutrient-rich
growth factors.
• Protection: Used as an adhesion barrier to help protect
tendons and nerves. For homologous use only.
• Regenerative: High concentration of growth factors
that reduce inflammation and scarring
• Easy to use: Membranes are rehydrated quickly
in the surgical site
• Convenient: Ambient storage (membranes)
with a 5-year shelf life
• Safe: Recovered aseptically and DMSO free

Applications and Benefits:

• Tendon or nerve wrap Arthrex Amnion Matrix - Cord
• Adhesion barrier
• Reduces scar formation
• Growth factors direct to site
• Rich in growth factors

Arthrex Amnion Matrix extracellular membrane is available in 2 thicknesses and a variety of sizes:
Arthrex Amnion Matrix - Thin
This traditional single layer is a semitransparent
collagenous membrane approximately 100 μm-
300 μm in thickness. As with the thicker version,
Arthrex Amnion Matrix - Thin is intended for use
as a soft-tissue barrier or wound covering.
2 cm x 2 cm ABS-4100-022
2 cm x 3 cm ABS-4100-023
4 cm x 4 cm ABS-4100-044
4 cm x 6 cm ABS-4100-046
7 cm x 7 cm ABS-4100-077
Arthrex Amnion Matrix - Cord
Approximately 8x thicker than traditional Amnion,
Arthrex Amnion Matrix - Cord can be sutured and
is easy to handle. Arthrex Amnion Matrix - Cord is
derived from the umbilical cord and is approximately
8x thicker than Arthrex Amnion Matrix - Thin, which
allows for suturing and easy handling.
2 cm x 2 cm ABS-4200-022
2 cm x 3 cm ABS-4200-023
3 cm x 4 cm ABS-4200-034
3 cm x 6 cm ABS-4200-036
3 cm x 8 cm ABS-4200-038

Arthrex Amnion Viscous is amniotic fluid

that contains a broad spectrum of growth
factors and cytokines that play an important
role in wound healing, cell proliferation,
tissue protection and repair.21 Arthrex
Amnion Viscous is available in convenient
sizes for a variety of applications and
has a 2-year shelf life.
0.5 cc ABS-4300-050
1.0 cc ABS-4300-100
2.0 cc ABS-4300-200

24
SOFT TISSUE ArthroFLEX®* Dermal Allograft
ArthroFLEX dermal allograft is an acellular dermal extracellular matrix intended for supplemental support
and covering for soft-tissue repair. MatrACELL®* decellularized dermis, a patented and validated process
by LifeNet Health®, renders the ArthroFLEX allograft dermis acellular, without compromising biomechanical
or biochemical properties. This process allows the matrix to retain its growth factors, native collagen scaffold,
and elastin, which are required for healing.

This patented and validated process renders allograft bioimplants acellular, without compromising the
biomechanical or desired biochemical properties of an allograft bioimplant for its intended surgical application.

Features and Benefits:

• An intact acellular matrix of collagen, elastin, and growth factors provides a clean scaffold intended
for supplemental support and covering for soft-tissue repair
• Elastin and collagen provide unparalleled strength for supplemental support and covering for
soft-tissue repair
• Short processing time reduces the opportunity for water-mediated lysis of the natural collagen
and elastin scaffold
• MatrACELL decellularized dermis removes donor DNA from the dermal matrix, ensuring a biocompatible
scaffold to facilitate repair
• Uses a validated DNA assessment method, able to detect as little
as one nanogram (ng/mL) of nucleic acid to ensure the tissue has
been decellularized
• Uses multiple disinfecting agents to provide comprehensive
tissue disinfection
• Terminally sterilized with a 3-year shelf life

LifeNet Health Part Number

Decellularized Dermis, 35 mm x 35 mm x 1.5 mm AFLEX100
Decellularized Dermis, 40 mm x 70 mm x 1.5 mm AFLEX101
Decellularized Dermis, 35 mm x 35 mm x 2.0 mm AFLEX200
Decellularized Dermis, 40 mm x 40 mm x 1.0 mm AFLEX400
Decellularized Dermis, 40 mm x 70 mm x 1.0 mm AFLEX401
Decellularized Dermis, 15 mm x 140 mm x 1.5 mm AFLEX150
Decellularized Dermis, 50 mm x 90 mm x 1.5 mm AFLEX103
Decellularized Dermis, 30 mm x 40 mm x .5 mm AFLEX500
Decellularized Dermis, 40 mm x 70 mm x 2.0 mm AFLEX201
Decellularized Dermis, 40 mm x 70 mm x 3.0 mm AFLEX301
BioWashers, 10 mm x 14 mm x 2.0 mm AFLEX822

Superior Capsular Reconstruction

*ArthroFLEX and MatrACELL BioWasher® Human Allograft Tissue

are registered trademarks OR Human Dermal Tissue AFLEX-822
25 of LifeNet Health.
Arthrex DX Reinforcement Matrix

SOFT TISSUE
The Arthrex DX Reinforcement Matrix is a dermal extracellular matrix (ECM) that has been created as
a biomechanically strong and biocompatible scaffold for the reinforcement and repair of soft tissues.
By maintaining the natural 3D structure and natural vascular channels through the OPTRIX™* processing
technology, Arthrex is providing a sterile, ready-to-use, biologically intact scaffold while maintaining
essential matrix components such as collagen, elastin, glycoproteins, glycosaminoglycans,
and proteoglycans.
Collagen
Features and Benefits: Provides strength
and structural
support
• Retains native matrix structure for superior strength
and support for cellular migration22
• Removes antigenic components, while maintaining
high level of collagen structure Glycosaminoglycans Elastin
• Porous, open structure providing a scaffold for cell ingrowth Mediates cell Provides elasticity
communication for the tissues
• Excellent strength without crosslinking
• Higher modulus than competitive products22
• Validated preservation of ECM proteins and growth factors22
• Convenience
– Room temperature storage
– Prehydrated
– No preparation time Glycoproteins Proteoglycans
– Two-year shelf life Promotes cell Sequesters growth
attachment factors
• Safety
– Sterile
– Reduced a-Gal antigen
– Biocompatible Arthrex DX Reinforcement Matrix Components
– OPTRIX™ process
– Every lot tested to confirm DNA and cellular removal
– Retains biologic integrity

Decellularized Xenograft Dermis, Hydrated 5.0 cm x 5.0 cm x 1.5 mm ABS-30001S

Decellularized Xenograft Dermis, Hydrated 6.0 cm x 8.0 cm x 1.5 mm ABS-30002S

The Arthrex DX Reinforcement Matrix is supplied sterile and comes

prehydrated, with saline already in the package, and ready to use.

SpeedBridge™ RCR with

DX Reinforcement Matrix

*OPTRIX is a trademark of DSM. 26

SOFT TISSUE Tendon Allografts – Construct Grafts
Use of allograft tendons for primary and revision ACL and PCL reconstructions reduces OR time
and eliminates the risk of donor site morbidity. Other uses of allograft tendons include reconstruction
of the medial and lateral collateral ligaments of the knee (MCL, LCL), elbow ligament reconstruction,
and medial and lateral ankle stabilization procedures, just to list a few. Tendons offered by Arthrex
are provided sterile from tissue bank alliance partners. The processing methods used render the
tissue sterile without compromising the biomechanical or biochemical properties of the tissue.

Construct Grafts JRF Ortho Part Number LifeNet Health Part Number
Presutured Allograft GraftLink® Construct FGL
Presutured Lateral Ankle Tendon LAT-001 FPSST
JRF GraftLink XL Construct (PCL) GRX-001
KinetiGraft BTB Construct FKG10
SpeedGraft® Construct SPD-001
VersaGraft® Construct VRG-001
ACL Reconstruction using the
Presutured Allograft GraftLink®
Construct

VersaGraft® Presutured
Tendon for Lateral Ankle
Reconstruction

SpeedGraft® Presutured
Double-Stranded Tendon

Lateral Ankle Reconstruction with the Presutured

Lateral Ankle Tendon

27 Not all products are available in Canada.

Tendon Allografts – Standard Grafts

SOFT TISSUE
Use of allograft tendons for primary and revision ACL and PCL reconstructions reduces OR time
and eliminates the risk of donor site morbidity.23
JRF Ortho Part Number
Standard Grafts Allosource /CTS LifeNet Health Part Number
Achilles Tendon w/ Bone Block 10017000/1025-14 FATB
Achilles Tendon w/o Bone Block 1085-14 FAT
All-Inside Single/Anterior Tibialis Tendon D = 8.0 mm-11.0 mm, L = 170 mm-200 mm FANT-SL
All-Inside Single/Posterior Tibialis Tendon D = 8.0 mm-11.0 mm, L = 170 mm-200 mm FPOST-SL
All-Inside Single/Peroneus Longus Tendon D = 8.0 mm-11.0 mm, L = 170 mm-200 mm FPLT-SL
All-Inside Double D = 1 ea 6.0 mm + 1 ea 5 mm-7 mm, L = 170 mm-200 mm FDBLTEND
Anterior Tibialis Tendon 1020-14 FANT/TIB/T
Double Bundle Tibialis Tendon FDBLTEND
Extensor Mechanism, Right 24818001
Extensor Mechanism, Left 24818002
Gracilis, Double Strand 26217000/1009-14
Osteotomy Wedge, Pair 41915001
Patellar Tendon, Bisected/Hemi 1781700/1166-14 FBPL
Patellar Tendon, Bisected, Small Block FBPLSB
Patellar Tendon, Whole 17917000/1165-14 FWPL
Patellar Tendon, Whole - Small Block FWPLSB
Patellar Tendon, Whole with Quadriceps 1013-14 FWPLQ
Peroneus Longus, Double Strand 43917000/1170-14
Peroneus Tendon 1170-14 FPLT
Pre-Shaped Achilles, 10 mm 10017100/1967-14 FATB10
Pre-Shaped Achilles, 11 mm 1968-14 FATB11
Pre-Shaped Patellar Tendon, 10 mm 18017000/1964-14 FPL10
Pre-Shaped Patellar Tendon, 11 mm 1965-14 FPL11
Posterior Tibialis Tendon 1021-14 FPOST.TIBIAL
Quadruple Strand Semitendinosus/Gracilis 42217002/1501-14
Quadruple Strand Tibialis 44217000
Quadruple Strand Peroneous Longus 44217004
Quadriceps Tendon w/Bone 1903-14
Rotator Cuff Patch Graft 47015000
Semi-Tendinosus, Double Strand 18717000/1014-14
Semi-Tendinosus and Gracilis Tendons 1501-14 1FST+1FGRACILIS
Semi-Tendinosus Tendon Min L = 230 mm, Min D > 4.0 mm 1014-14 FST
Semi-Tendinosus Tendon L = 160 mm-180 mm, D = 4 mm-6 mm 44317003/1824-14 FSTP
Tibialis, Anterior, Double Strand 41517000/1020-14
Tibialis, Posterior, Double Strand 41617000/1021-14
Anterior Tibialis Tendon/Small Joint 44317000 FANT-SL
Gracilis Tendon/Small Joint 44317002 FGRACILIS
Peroneus Longus/Small Joint 44317002 FPLT-SL
Posterior Tibialis Tendon/Small Joint 44317001 FPOST-SL
Fascia Lata, Small 30 mm x 60 mm FL S
Fascia Lata, Medium 30 mm x 150 mm FL M
Fascia Lata, Large 80 mm x 200 mm FL L
RC Allograft Patch, Size Varies - 2.0 mm-25 mm x 2.0 mm-2.5 mm 47015000
GraftRope FROPE

ACL Graft Fixation

with TightRope® RT and
GraftLink® Construct

Tibialis Tendons

28
WOUND CARE JumpStart® Antimicrobial Wound Dressing
JumpStart is a microcurrent-generating antimicrobial wound
dressing designed to mimic the body’s natural physiologic
electric currents. Used in multiple clinical applications, JumpStart
dressing provides sustained broad-spectrum antimicrobial24
efficacy and an optimal environment for wound healing.

The Technology
The dot matrix pattern of silver and zinc microcell batteries
embedded on the dressing generate microcurrents in the
presence of a conductive medium, such as sterile saline,
water, hydrogel, or wound exudate.

JumpStart dressings are provided on an ultrathin,

lightweight, polyester substrate and contain laser-cut
fenestration to allow easy passage of wound exudate into
the absorbent layer or a secondary dressing. The flexible
design easily contours to the body. JumpStart dressings
may be applied directly over sutures, staples, Steri-Strip™*
skin closures and liquid skin adhesives.

JumpStart Composite Dressing

Foam Layer Electricity acts as a guidance signal to initiate
• Absorbent for effective cell migration and reepithelialization.
exudate management Published data on file.28

JumpStart Contact Layer Dressing

• Multiple sizes available to fit surgical and wound sites
• Conforms easily to body contours for patient comfort
• Can be cut to fit under secondary dressings

Adhesive Layer
• High performance and
waterproof for multiday wear
• Ergonomic shape conforms easily to body
contours for adherence and patient comfort
Technology
JumpStart Contact Layer Dressing Layer
Dressing Size (in) Qty/Box Arthrex Part#

1 x 1 Fenestrated 10 ABS-4001
Dot matrix of elemental
1.5 x 8 10 ABS-4005
silver and zinc create
1.5 x 10 10 ABS-4006
microcell batteries that
2 x 2 10 ABS-4002
generate microcurrents in the
2 x 5 10 ABS-4025
presence of a conductive
3 x 3 10 ABS-4003
medium.
4 x 4 10 ABS-4004
8 x 8 1 ABS-4008
12 x 12 1 ABS-4012 Broad Spectrum Antimicrobial Efficacy
JumpStart Composite Dressing JumpStart dressing’s antimicrobial protection
Adhesive Size (in) Dressing Size (in) Qty/Box Arthrex Part# creates an optimal environment for wound
healing.24-27
2.5 Diameter 1.0 Diameter 10 ABS-4054 • Kills a broad spectrum of harmful pathogens, including
4.0 Diameter 2.0 Diameter 10 ABS-4056 multidrug resistant21 and biofilm-forming bacteria25-27
4 x 4 2 x 2 5 ABS-4053
to help reduce risk of infection
5 x 6 1.5 x 5 5 ABS-4051
4.5 x 10 1.5 x 7 5 ABS-4052 • No silver release into the bloodstream29
6 x 11.5 2 x 9 5 ABS-4050

29 *Steri-Strip is a trademark of 3M.

ProWick®* Postoperative Dressing and Cold Therapy System

WOUND CARE
The ProWick shoulder postoperative dressing and cold therapy system is revolutionary technology
designed to meet the demands of arthroscopic and mini open surgical techniques.

ProWick systems feature a tapeless design composed of state-of-the-art, super-absorbent material that
stores patient exudate away from the surgical incision sites while compression and cold therapy are
applied to the healing joint.

Features and Benefits: c

• Super-Absorbent: Hydrophilic foam islands cover d
incision sites and channel fluid into the super-absorbent
cover dressing, a fluid reservoir

• Compression: Conforming strap gently compresses

swollen joint and secures cover dressing to the body,
eliminating the need for tape

• Efficient Cold Therapy: Cold therapy takes advantage

of the thin ProWick dressing system, creating an e b
effective alternative to traditional bulky dressings a

The Sterile ProWick Shoulder

Sterile ProWick Shoulder Dressing System Dressing System Includes:
• Two foam islands (a)
Foam Islands:
• Super-absorbent cover dressing (b)
• Hydrophilic foam islands absorb fluid into the cover
dressing and away from incision sites, minimizing pooling • Three conforming compression straps (c)
• Reusable cold therapy wrap (d)
Super-Absorbent Cover Dressing (Fluid Reservoir): • Five waterproof bandages for
• Triple-layer dressing stores exudate away from incision sites post-dressing home use (e)
• Ultralow profile reduces bulk, enabling effective cold therapy
• Absorbs several ounces of fluid

Compression Straps:
• Secures dressing without tape; no painful tape removal
• Applies light compression and provides joint support
• Conforms to joint as swelling decreases, so dressing
stays comfortably in place Compression Strap
Super-Absorbent
Cold Pack: Cover Dressing
• Cost-effective reusable cold therapy Foam Island
• Cold therapy easily penetrates low-profile cover dressing
• Enables patient mobility while cold therapy is applied

Waterproof Bandages:
• Keep incisions clean and dry after removal of cover dressing
• Conveniently packaged to send home with patient
Foam islands channel
ProWick Shoulder Postoperative Dressing and Cold Therapy System AR-1625P exudate from incision
(box of 10, packed individually, sterile) and into cover dressing

ProWick Knee Postoperative Dressing and Cold Therapy System AR-1626P

(box of 10, packed individually, sterile)

*ProWick is a registered trademark of Redyns Medical LLC. 30

REFERENCES References
1. Scott A, Khan KM, Roberts CR, Cook JL, Duronio V. What do we mean by the term “inflammation“? A contemporary basic science update
for sports medicine. Br J Sports Med. 2004;38(3):372-380. doi:10.1136/bjsm.2004.011312.

2. Jiang N, Tan NS, Ho B, Ding JL. Respiratory protein-generated reactive oxygen species as an antimicrobial strategy. Nat Immunol.
2007;8(10):1114-1122. doi:10.1038/ni1501.

3. Knutsen G1, Engebretsen L, Ludvigsen TC, et al. Autologous chondrocyte implantation compared with microfracture in the knee.
J Bone Joint Surg Am. 2004;86-A(3):455-464.

4. Kramer J1, Böhrnsen F, Lindner U, et al. In vivo matrix-guided human mesenchymal stem cells. Cell Mol Life Sci. 2006;63(5):616-626.
doi:10.1007/s00018-005-5527-z.

5. Hernigou PH, Poignard A, Beaujean F, Rouard H. Percutaneous autologous bone marrow grafting for nonunions: Influence
of the number and concentration of progenitor cells. J Bone Joint Surg Am. 2005;87(7):1430-1437. doi:10.2106/JBJS.D.02215.

6. Connolly JF, Guse R, Tiedeman J, Dehne R. Autologous marrow injection as a substitute for operative grafting of tibial nonunions.
Clin Orthop Relat Res. 1991;(266):259-270.

7. Lim JK, Hui J, Li L, Thambyah A, Goh J, Lee EH. Enhancement of tendon graft osteointegration using mesenchymal stem cells
in a rabbit model of anterior cruciate ligament reconstruction. Arthroscopy. 2004;20(9):899-910. doi:10.1016/j.arthro.2004.06.035.

8. Ouyang HW, Goh JC, Lee EH. Use of bone marrow stromal cells for tendon graft-to-bone healing: Histological and immunohistochemical
studies in a rabbit model. Am J Sports Med. 2004;32(2):321-327. doi:10.1177/0095399703258682.

9. Choi LS, Ma R, Zeng Q, et al. Bone marrow aspirate with or without platelet concentrates as a bone graft substitute for posterolateral spinal
fusion: A randomized, controlled study using an animal model. 52nd Annual Meeting of the Orthopedic Research Society. Paper No: 1742.

10. Pountos I, Jones E, Tzioupis C, McGonagle D, Giannoudis PV. Growing bone and cartilage: the role of mesenchymal stem cells.
J Bone Joint Surg (Br). 2006;88-B:421-426. doi:10.1302/0301-620X.88B4.

1 1 . Hernigou P, Poignard A, Beaujean F, Rouard H. Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number
and concentration of progenitor cells. J Bone Joint Surg Am. 2005;87(7):1430-1437. doi:10.2106/JBJS.D.02215.

12. Sánchez M, Delgado D, Sánchez P, et al. Combination of intra-articular and intraosseous injections of platelet rich plasma for severe knee
osteoarthritis: a pilot study [published online July 4, 2016]. Biomed Res Int. doi:10.1155/2016/4868613.

13. CellRight Technologies, LLC. Data on file (ConCelltrate® 100 Histology and In-Vitro Alkaline Phosphate Induction Assay). Universal City, TX; 2017.

14. Tanaka T1, Kumagae Y, Saito M, et al. Bone formation and resorption in patients after implantation of beta-tricalcium phosphate blocks with 60%
and 75% porosity in opening-wedge high tibial osteotomy. J Biomed Mater Res B Appl Biomater. 2008;86(2):453-459. doi:10.1002/jbm.b.31041.

15. Dong J1, Uemura T, Shirasaki Y, Tateishi T. Promotion of bone formation using highly pure porous beta-TCP combined with bone marrow-derived
osteoprogenitor cells. Biomaterials. 2002;23(23):4493-4502.

16. Cheng NC1, Estes BT, Awad HA, Guilak F. Chondrogenic differentiation of adipose-derived adult stem cells by a porous scaffold derived from
native articular cartilage extracellular matrix. Tissue Eng Part A. 2009;15(2):231-241. doi:10.1089/ten.tea.2008.0253.

17. Chadha N, Dang A, Sampson E, et al. Porous cartilage-derived matrix scaffolds for repair of articular cartilage defects. ORS. 2012;Poster No: 0735.

18. Malinin T, Temple HT, Carpenter EM. Induction of regeneration of articular cartilage defects by freeze-dried particulate cartilage allografts.
ICRS. 2009 meeting; poster presentation.

19. Arthrex, Inc. and Osiris Therapeutics, Inc. LA1-00007-EN_A. Naples, FL; 2015.

20. Chen MI1, Branch TP, Hutton WC. Is it important to secure the horns during lateral meniscal transplantation? A cadaveric study.
Arthroscopy. 1996;12(2):174-181.

21. Bazrafshan A, Owji M, Yazdani M, Varedi M. Activation of mitosis and angiogenesis in diabetes-impaired wound healing by processed human
amniotic fluid. J Surg Res. 2014;188(2):545-552. doi:10.1016/j.jss.2014.01.041.

22. Hoganson DM, O‘Doherty EM, Owens GE, et al. The retention of extracellular matrix proteins and angiogenic and mitogenic cytokines
in a decellularized porcine dermis. Biomaterials. 2010;31(26):6730-6737. doi:10.1016/j.biomaterials.2010.05.019.

23. Poehling GG, Curl WW, Lee CA, et al. Analysis of outcomes of anterior cruciate ligament repair with 5-year follow-up: allograft versus autograft.
Arthroscopy. 2005;21 (7):774-785. doi:10.1016/j.arthro.2005.04.112.

24. Kim H, Makin I, Skiba J, et al. Improvement of human keratinocyte migration by a redox active bioelectric dressing.
PLoS ONE 9(3):e89239. doi:10.1371/journal.pone.0089239.

25. Banerjee J, Ghatak P, Roy S, et al. Antibacterial efficacy testing of a bioelectric wound dressing against clinical wound pathogens.
Open Microbiol J. 2014;8:15-21. doi:10.2174/1874285801408010015.

26. Kim H, Skiba J, Makin I, Izadjoo M. Evaluating anti-biofilm efficacy of a wound dressing in mono- and multi-species poloxamer biofilms.
Presented at the Symposium on Advanced Wound Care. Las Vegas, NV 2014;(suppl):LB024.

27. Banerjee J, Das Ghatak P, Roy S, et al. Silver-zinc redox-coupled electroceutical wound dressing disrupts bacterial biofilm.
PLoS One. 2015;10(3):e0119531. doi:10.1371/journal.pone.0119531/eCollection.2015.

28. Zhao M. Electrical fields in wound healing-an overriding signal that directs cell migration. Semin Cell Dev Biol. 2009;20(6):674-682.
doi:10.1016/j.semcdb.2008.12.009.

29. Park SS, Kim H, Makin IR, Skiba JB, Izadjoo MJ. Measurement of microelectric potentials for a bioelectrically-active wound care device
in the presence of bacteria. J Wound Care. 2015;24(1):23-33. doi:10.12968/jowc.2015.24.1.23.

To order products, please call Arthrex at: 1.800.934.4404

31
 ORTHOBIOLOGICS OVERVIEW
The market for orthobiologics is continually gaining attention owing to the compelling benefits
of cellular therapies, allografts, and innovative technologies in expediting skeletal and tissue healing.
Focused on patient safety and clinical outcomes, Arthrex is leading the way in the field of
orthobiologics. Additionally, we are developing new technologies with potential multispecialty
applications. We will continue to develop a wide range of innovative products
to strengthen our portfolio and to help surgeons treat their patients better.
 This description of technique is provided as an educational tool and clinical aid to assist properly licensed medical professionals
in the usage of specific Arthrex products. As part of this professional usage, the medical professional must use their professional
judgment in making any final determinations in product usage and technique. In doing so, the medical professional should rely
on their own training and experience and should conduct a thorough review of pertinent medical literature and the product’s
Directions For Use. Postoperative management is patient specific and dependent on the treating professional’s assessment.
Individual results will vary and not all patients will experience the same postoperative activity level or outcomes.

View U.S. Patent information at www.arthrex.com/corporate/virtual-patent-marking

© 2018 Arthrex, Inc. All rights reserved. LB1-0804-EN_I